Retatrutide, developed by Soma, represents a significant breakthrough in metabolic regulation. This dual-action drug combines hormonal receptor agonist activity with another receptor activation , demonstrating impressive potential in trial data for metabolic loss . Scientists believe Retatrutide could provide a alternative option for people experie